Assay Report
Methods · Standard Curves · QC · Results
Ultra-sensitive multi-color fluorophore-linked immunospot (FluoroSpot) services for simultaneously enumerating single-cell secretion and multi-cytokine co-secretion of key effector molecules—including IFN-γ, IL-2, TNF-α, Granzyme B, IL-17A, and IL-10—from human, non-human primate (NHP), and rodent peripheral blood mononuclear cells (PBMCs) down to 1 in 1,000,000 cells.
By resolving individual single-, dual-, triple-, and quadruple-secreting polyfunctional T-cell subpopulations at single-cell resolution, our FluoroSpot platform provides the benchmark immunological correlate for CAR-T potency, neoantigen cancer vaccine efficacy, and durable viral memory.
Universal experimental design dimensions ensuring sound biological comparison and analytical specificity.
| Planning Dimension | Core Parameters Defined Collaboratively | Impact on Data Integrity & Interpretation |
|---|---|---|
| Stimulation Formulation | Overlapping peptide pools (15-mers with 11-aa overlap), recombinant protein, or whole viral/capsid antigen | Directs MHC Class I (CD8+) vs. Class II (CD4+) presentation pathways without non-specific bystander activation. |
| Control Arm Design | Negative control (DMSO/media background <5 SFU/well), Positive control (phytohemagglutinin [PHA] / PMA-ionomycin >500 SFU/well), Recall control (CEFX pool) | Guarantees analytical specificity and validates baseline cell viability and T-cell responsiveness. |
| Incubation Kinetics | 18–24 hours (acute Th1/cytotoxic response) vs. 40–48 hours (delayed memory or B-cell ASC activation) | Captures peak active secretion while preventing cell exhaustion or secondary bystander cytokine cascades. |
| Polyfunctional Combinations | Selecting IFN-γ/IL-2/TNF-α (Th1/Vaccine memory) vs. IFN-γ/IL-2/Granzyme B (Cytotoxic T cell potency) | Tailors secretor profiling directly to the drug candidate's mechanism of action (e.g., CAR-T, neoantigen vaccine). |
| Plate Randomization & Layout | Pre-dose baseline and longitudinal post-treatment timepoints balanced across multi-well plates | Eliminates confounding between true therapeutic immunogenicity and run-to-run bioanalytical variance. |
Validated multi-color FluoroSpot combinations for translational cellular immune monitoring.
| Panel Configuration | Core Secreted Analytes | Fluorophore Channels & Wavelengths | Primary Research & Application Focus |
|---|---|---|---|
| Human Polyfunctional Th1 Panel | IFN-γ + IL-2 + TNF-α | 490 nm (FITC) / 550 nm (Cy3) / 640 nm (Cy5) | Core vaccine immunogenicity, viral memory durability, and CD4+/CD8+ Th1 polarization quality. |
| T Cell Cytotoxicity & Killing Panel | IFN-γ + Granzyme B + Perforin | 490 nm (FITC) / 550 nm (Cy3) / 640 nm (Cy5) | CAR-T/TCR-T in vitro potency, target cell-mediated lysis, and cytotoxic CD8+ effector release kinetics. |
| Th1 / Th2 / Th17 Tri-Polarization | IFN-γ (Th1) + IL-4 (Th2) + IL-17A (Th17) | Multi-color LED fluorescent filters | Autoimmune disease modeling, mucosal barrier immunity, and adjuvant skewing characterization. |
| Regulatory & Tolerogenic T Cell Panel | IL-10 + IFN-γ + IL-2 | 490 nm (FITC) / 550 nm (Cy3) / 640 nm (Cy5) | Immune tolerance induction, regulatory T-cell suppressive profiling, and chronic viral persistence. |
| Non-Human Primate & Rodent Panels | Species-specific IFN-γ + IL-2 + TNF-α | Qualified cynomolgus, rhesus, mouse, rat reagents | Preclinical translational safety, NHP vaccine challenge models, and rodent efficacy studies. |
Evaluating analytical sensitivity, single-cell co-secretion resolution, and throughput across cellular platforms.
| Technical Dimension | Conventional Enzymatic ELISpot | Multi-Color FluoroSpot (Our Service) | Flow Cytometry ICS | Soluble Cytokine Multiplex |
|---|---|---|---|---|
| Primary Output | Single analyte frequency (1 spot/well) | Simultaneous co-secretion (1–4 targets) | Intracellular protein accumulation | Total accumulated fluid concentration |
| Frequency Sensitivity (LOD) | 1 in 100,000 to 1 in 1,000,000 | 1 in 100,000 to 1 in 1,000,000 | ~1 in 1,000 to 1 in 2,000 | 0.010 – 5.0 pg/mL (Matrix dependent) |
| Co-Secretion Discrimination | No (Single color per well) | Yes (Single/dual/triple/quad secretors) | Yes (Multi-color intracellular) | No (Cumulative bulk average) |
| Physiological State | True active secretion | True active secretion | Trapped by Brefeldin A | Secreted & accumulated |
| Cell Input Requirements | 100,000 – 250,000 cells/well | 100,000 – 250,000 cells/well | 1,000,000+ cells/test | Cell-free supernatant |
| Throughput & Automation | High (96-well automated) | High (Automated RAWspot analysis) | Moderate (Flow acquisition) | High (96/384-well automated) |
Optical precision, multi-channel LED deconvolution, and MIATA-compliant data governance.
Narrow-band LED excitation sources (FITC, Cy3, Cy5, LED640) and hard-coated filter sets eliminate spectral bleed-through across multiplex fluorescent spots.
Advanced pixel-level intensity algorithms accurately separate overlapping spots without subjective thresholding, computing Relative Spot Volumes (RSV).
Standardized documentation of sample handling, cell viability, negative background thresholds, and positive control responsiveness across all analytical plates.
Controlled thawing of cryopreserved PBMCs/splenocytes with Benzonase nuclease; automated viability screening (threshold >80%).
Seeding 100,000–250,000 viable cells per well into pre-coated low-fluorescent PVDF membrane plates with synthetic peptide pools or target cells.
Incubation for 18–24 hours at 37°C in humidified 5% CO2 incubators without physical vibration.
Cell removal, plate washing, and incubation with cocktail of matched fluorophore-conjugated detection antibodies (e.g., anti-IFN-γ-490, anti-IL-2-550, anti-TNF-α-640).
Automated acquisition on Mabtech IRIS reader, single- and co-secreting spot deconvolution, and delivery of normalized SFU/10^6 cell datasets.
Standardized pre-analytical cell handling protocols ensuring membrane integrity and functional responsiveness.
| Pre-Analytical Parameter | Why It Matters for FluoroSpot Testing | Intake Specification & Recommendation |
|---|---|---|
| PBMC Isolation Timing | Delayed separation of whole blood at room temperature causes granulocyte activation and blunted T-cell responses. | Isolate PBMCs via density gradient centrifugation (Ficoll-Paque) within 8 hours of blood collection. |
| Cryopreservation Quality | Suboptimal freezing rates compromise membrane integrity and secretory viability upon thawing. | Resuspend in pre-chilled freezing medium (90% FBS + 10% DMSO or CryoStor CS10); freeze at -1°C/min. |
| Post-Thaw Cell Viability | Dying cells release DNA and non-specific proteases, increasing background noise and suppressing antigen-specific activation. | Cell viability must exceed 80%; include a 1–2 hour recovery resting phase at 37°C prior to plating. |
| Input Cell Quantity | Accurate frequency calculation requires standardized cell seeding densities across duplicate/triplicate wells. | Provide minimum 5–10 × 10^6 cryopreserved viable cells per donor/sample to support complete assay matrices. |
| Stimulus Solubilization | Residual DMSO concentrations >0.5% in culture media induce non-specific cytotoxicity and spot inhibition. | Reconstitute peptide pools in sterile DMSO/PBS; ensure final in-well DMSO concentration is strictly <0.25% v/v. |
Applying multi-color single-cell co-secretion enumeration across vaccines, cellular therapies, and neoantigen profiling.
Quantify polyfunctional IFN-γ+/IL-2+/TNF-α+ triple-secreting CD4+/CD8+ memory T-cell frequencies to evaluate vaccine durability.
Measure dual Granzyme B and IFN-γ release at single-cell resolution upon co-culture with target-expressing tumor cells (CAR-T Potency).
Verify immunogenicity and polyfunctional effector capacity of predicted patient-specific neoepitope peptide pools.
Monitor long-term cellular immune memory against chronic and emerging viral pathogens (SARS-CoV-2, CMV, EBV, Influenza, HIV).
Profile shift from Th1/Th17 inflammatory effector secretion toward IL-10 regulatory phenotypes in autoimmune disease models.
Screen donor PBMCs for cellular reactivity against viral delivery vectors (AAV Capsid Immunogenicity).
Standardized bioanalytical documentation, annotated spot images, and senior immunologist consultation.
Key peer-reviewed publications establishing multi-color deconvolution principles and translational immune correlates.
Study Design Takeaway: Validates multi-color FluoroSpot for simultaneously resolving distinct cytokine co-secretion patterns at single-cell resolution without cellular cross-talk.
Study Design Takeaway: Demonstrates that T-cell polyfunctionality (simultaneous IFN-γ, IL-2, and TNF-α secretion) correlates directly with vaccine protection and long-term immune memory.
Study Design Takeaway: Establishes standardized validation criteria for FluoroSpot in clinical trial monitoring, highlighting superior sensitivity over flow cytometry ICS.
Study Design Takeaway: Outlines optimized protocols for high-throughput peptide matrix screening and spot counting criteria in multi-analyte cellular assays.
Addressing common project planning, cell handling, and assay selection inquiries.
FluoroSpot uses distinct fluorophores to measure multiple cytokines (up to 4 analytes) secreted simultaneously by individual cells in the same well, enabling identification of polyfunctional T-cell subpopulations (e.g., dual IFN-γ+/IL-2+ or triple IFN-γ+/IL-2+/TNF-α+ secretors). Conventional ELISpot can only measure one analyte per well.
FluoroSpot is 100- to 1,000-fold more sensitive than ICS, detecting rare antigen-specific secretors at frequencies as low as 1 in 1,000,000 cells without requiring toxic protein transport inhibitors (brefeldin A). Flow cytometry is preferred when detailed cell surface phenotyping is required.
Standard protocols require 100,000 to 250,000 viable cells per well. Including background negative controls, positive controls, and duplicate/triplicate wells, we typically recommend providing 5–10 × 10^6 cryopreserved viable PBMCs per donor/sample.
Relative Spot Volume (RSV) is a metric calculated by Mabtech RAWspot software that integrates spot area and fluorescent intensity at the spot center, providing a quantitative measurement of the total amount of cytokine secreted per individual cell.
Every run incorporates negative control wells (unstimulated cells / vehicle <5 SFU/well), positive control wells (polyclonal stimulators PHA or anti-CD3/CD28 >500 SFU/well), and viral recall controls (CEFX peptide pool) to verify cell viability, baseline responsiveness, and assay specificity.
No. All bioanalysis services provided by Creative Proteomics are strictly for Research Use Only (RUO). They are intended for preclinical drug discovery, animal disease models, translational research cohorts, and in vitro cellular characterization, and are not intended for clinical diagnostic or patient management procedures.
Demo Assay Report
Request a representative report to review how assay methods, standard curves, quality-control metrics, and quantitative results are presented.
Online Inquiry
×